<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539213</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457A2225</org_study_id>
    <secondary_id>2011-002929-21</secondary_id>
    <nct_id>NCT01539213</nct_id>
  </id_info>
  <brief_title>Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg</brief_title>
  <acronym>OFM ISF</acronym>
  <official_title>An Exploratory Study to Investigate the Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid Using Open Flow Microperfusion After a Single Subcutaneous Administration of 300 mg in Healthy Subjects and Psoriatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed exploratory study aims to understand the in vivo skin distribution properties of&#xD;
      subcutaneously (s.c.) administered AIN457 in psoriatic and healthy skin using open flow&#xD;
      microperfusion (OFM). The data of this study will help to understand the mode of action of&#xD;
      AIN457 in its target tissue.&#xD;
&#xD;
      It aims to establish a technique assessing in vivo distribution of AIN457 and its metabolites&#xD;
      in human dermal interstitial fluid (ISF) and exploring a potential pharmacodynamic effect in&#xD;
      situ. In addition, the study will further evaluate safety and local tolerability of&#xD;
      subcutaneously administered AIN457 and explore dermal interstitial fluid skin levels of&#xD;
      potential disease relevant biomarkers.&#xD;
&#xD;
      The study is divided into two parts - Part I with 8 healthy volunteers (HV) to validate the&#xD;
      method is completed and Part II with 8 psoriasis patients will start based on the outcome of&#xD;
      Part I.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount (ng/ml) of AIN457 in dermal interstitial fluid.</measure>
    <time_frame>Day 8</time_frame>
    <description>Distribution of AIN457 into dermal interstitial fluid after single subcutaneous administration of AIN457 in healthy subjects and in psoriatic patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount (ng/ml) of AIN457 in dermal interstitial fluid.</measure>
    <time_frame>Day 15</time_frame>
    <description>Distribution of AIN457 into dermal interstitial fluid after single subcutaneous administration of AIN457 in healthy subjects and in psoriatic patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events to measure Safety of subcutaneously administered AIN457 in healthy volunteers and psoriatic patients</measure>
    <time_frame>3 weeks</time_frame>
    <description>Safety of AIN457 s.c. injection will be documented as numbers of adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I only: concentration of sinistrin in serum vs. dermal interstitial fluid to confirm the ability of sinistrin to serve as reference to quantify AIN457 in dermal interstitial fluid.</measure>
    <time_frame>Day 8</time_frame>
    <description>Concentration of sinistrin in serum compared to dermal interstitial fluid.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>AIN457</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>secukinumab (AIN457)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>secukinumab (AIN457)</intervention_name>
    <description>anti-IL-17 antibody</description>
    <arm_group_label>AIN457</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For Part I : Healthy male and female subjects 18 to 65 years of age inclusive; For Part II:&#xD;
        Chronic plaque-type psoriasis (with or without arthritis) diagnosed for at least 6 months&#xD;
        before enrollment including at least one plaque accessible for OFM with at least moderate&#xD;
        severity ; Key exclusion criteria for Part I and Part II: Women of child-bearing potential&#xD;
        unwilling to use effective contraception; History of an ongoing, chronic or recurrent&#xD;
        infectious disease, or evidence of tuberculosis infection as defined by a positive TB-test&#xD;
        at screening; For Part I: Use of any prescription drugs, herbal supplements, within 4 weeks&#xD;
        prior to initial dosing For Part II: Ongoing use of concomitant psoriasis treatments.&#xD;
        Washout periods have to be adhered to.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=10883</url>
    <description>Results for CAIN457A2225 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <results_reference>
    <citation>Abstracts of the 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom. J Invest Dermatol. 2013 May;133 Suppl 1:S1-311.</citation>
    <PMID>23607128</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>December 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>interstitial fluid</keyword>
  <keyword>open flow microperfusion</keyword>
  <keyword>IL-17</keyword>
  <keyword>inflammatory skin disease</keyword>
  <keyword>scaly patches</keyword>
  <keyword>Healthy volunteers and psoriasis patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

